Search results
What is the treatment for epidermolysis bullosa acquisita? The primary aim in the treatment of EBA is to protect the skin and stop blister formation, promote healing and prevent complications.
29 paź 2023 · Objectives: Identify the clinical manifestations and symptoms of epidermolysis bullosa acquisita to facilitate early diagnosis. Implement evidence-based treatment strategies and appropriate diagnostic tests to confirm the diagnosis of epidermolysis bullosa acquisita and guide treatment decisions.
1 lut 2023 · Due to its recalcitrance conventional treatment of epidermolysis bullosa acquisita is shown to be demanding. Here we discuss novel therapeutic strategies that have emerged and which could potentially improve the quality of life in patients with EBA.
2 sie 2024 · Article02 March 2024. Pathogenetic Therapy of Epidermolysis Bullosa: Current State and Prospects. Article29 May 2021. Use our pre-submission checklist. FormalPara Key Summary Points. Targeted corrective therapies are the ultimate way of treating epidermolysis bullosa (EB). In vivo gene therapy is entering the stage of clinical application.
1 lut 2023 · Due to its recalcitrance conventional treatment of epidermolysis bullosa acquisita is shown to be demanding. Here we discuss novel therapeutic strategies that have emerged and which could potentially improve the quality of life in patients with EBA.
29 kwi 2024 · Epidermolysis bullosa acquisita (EBA) is a rare, sporadic, subepithelial, mucocutaneous blistering disease that usually develops in adulthood. EBA is classically described as a mechanobullous disorder characterized by skin fragility, noninflammatory tense bullae, milia, and scarring.
The picture can be indistinguishable from that of BP, regarding both clinical and laboratory aspects, as both show subepidermal bullae on histopathological examination, ... The use of rituximab in treatment of epidermolysis bullosa acquisita: Three new cases and a review of the literature. Dermatol Ther. 2018;31 doi: 10.1111/dth.12726.
